NATCO Pharma Unveils Generic Blood Cancer Treatment in US Market

Entertainment National Sports Markets Business & Economy Lifestyle World Astrology & Religion Technology Education & Jobs Auto Politics Viral Opinions

Loading more articles...

NATCO Pharma Launches Generic Blood Cancer Drug in US Market

Representational image (Image: News18)

N

News18•03-03-2026, 13:45

NATCO Pharma Launches Generic Blood Cancer Drug in US Market

•NATCO Pharma, in partnership with Breckenridge Pharmaceutical, Inc., launched generic Pomalidomide capsules in the US.
•Pomalidomide is a generic version of Celgene's Pomalyst, indicated for adult patients with blood and bone marrow cancer.
•The drug is available in 1mg, 2mg, 3mg, and 4mg strengths, distributed via specialty pharmacies and clinics.
•The launch strengthens NATCO's oncology and specialty portfolio, aiming to make specialty medicines accessible.
•Pomalidomide capsules are indicated for multiple myeloma and AIDS-related Kaposi sarcoma, with estimated US sales of USD 3.2 billion.

Read Full Article on News18 in English

✦

More like this

✦

More like this

Natco Pharma | Announces the launch of Pomalidomide Capsules in the US market used in the treatment of Adult patients with Multiple Myeloma. These capsules had estimated sales of $3.2 billion in the US for the 12 months that ended in September 2025.

Natco Pharma shares gain 3% on US launch of multiple myeloma drug

Aurobindo Pharma Shares Surge on USFDA Approval for Liver Transplant Drug

Aurobindo Pharma Shares Surge on USFDA Approval for Liver Transplant Drug

The BMC plans to start 25 more Aapla Dawakhana and three physiotherapy centres in the next financial year.

Alembic Pharma gets USFDA nod for Parkinson's drug, boosts US generics presence

Natco Pharma

Natco Pharma Shares Soar 2% on US Launch of Pomalidomide Capsules

Alembic Pharma gets USFDA nod for anti-seizure drug, stock volatile

Alembic Pharma gets USFDA nod for anti-seizure drug, stock volatile

Glenmark Wins US FDA Nod for Fluticasone Inhaler, Gets 180-Day Exclusivity

Glenmark Wins US FDA Nod for Fluticasone Inhaler, Gets 180-Day Exclusivity